Table 1.
Baseline characteristics of 6837 patients with esophageal cancer between 2006 and 2018 in Sweden, grouped according to the presence of an MDT
| No MDT n = 1338 |
MDT n = 5276 |
Missing n = 223 |
Total n = 6837 |
||
|---|---|---|---|---|---|
| Sex, no (%) | |||||
| Female | 384 (28.7%) | 1322 (25.1%) | 54 (24.2%) | 1760 (25.7%) | |
| Male | 954 (71.3%) | 3954 (74.9%) | 169 (75.8%) | 5077 (74.3%) | |
| Age, median (IQR) | |||||
| Years | 76 (66, 84) | 69 (62, 76) | 69 (61, 77) | 70 (63, 78) | |
| CCI No (%) | |||||
| 0 | 488 (36.5%) | 2150 (40.8%) | 103 (46.2%) | 2741 (40.1%) | |
| 1–2 | 192 (14.3%) | 719 (13.6%) | 40 (17.9%) | 951 (13.9%) | |
| 3 or above | 658 (49.2%) | 2407 (45.6%) | 80 (35.9%) | 3145 (46.0%) | |
| Clinical stage, no (%) | |||||
| Stage 0 | 19 (1.4%) | 33 (0.6%) | 1 (0.4%) | 53 (0.8%) | |
| Stage I | 38 (2.8%) | 152 (2.9%) | 7 (3.1%) | 197 (2.9%) | |
| Stage II | 115 (8.6%) | 758 (14.4%) | 22 (9.9%) | 895 (13.1%) | |
| Stage III | 150 (11.2%) | 1576 (29.9%) | 43 (19.3%) | 1769 (25.9%) | |
| Stage IVa | 38 (2.8%) | 509 (9.6%) | 11 (4.9%) | 558 (8.1%) | |
| Stage IVb | 516 (38.6%) | 1631 (30.9%) | 46 (20.6%) | 2193 (32.1%) | |
| Missing | 462 (34.5%) | 617 (11.7%) | 93 (41.7%) | 1172 (17.1) | |
| Clinical T-stage, no (%) | |||||
| Tis/HGD | 29 (2.2%) | 42 (0.8%) | 3 (1.3%) | 74 (1.1%) | |
| T1 | 64 (4.8%) | 192 (3.6%) | 9 (4.0%) | 265 (3.9%) | |
| T2 | 159 (11.9%) | 820 (15.5%) | 29 (13.0%) | 1008 (14.7%) | |
| T3 | 367 (27.4%) | 2637 (50.0%) | 62 (27.8%) | 3066 (44.9%) | |
| T4a | 165 (12.3%) | 724 (13.7%) | 27 (12.1%) | 916 (13.4%) | |
| T4b | 20 (1.5%) | 124 (2.4%) | 1 (0.4%) | 145 (2.1%) | |
| Missing | 534 (39.9%) | 737 (14.0%) | 92 (41.3%) | 1363 (19.9%) | |
| Clinical N-stage, no (%) | |||||
| N0 | 404 (30.2%) | 1991 (37.7%) | 42 (18.8%) | 2437 (35.6%) | |
| N1 | 330 (24.7%) | 1891 (35.8%) | 83 (37.2%) | 2304 (33.7%) | |
| N2 | 91 (6.8%) | 613 (11.6%) | 8 (3.6%) | 712 (10.4%) | |
| N3 | 49 (3.7%) | 419 (7.9%) | 7 (3.1%) | 475 (6.9%) | |
| Missing | 464 (34.7%) | 362 (6.9%) | 83 (37.2%) | 909 (13.3%) | |
| Clinical M-stage, no (%) | |||||
| M0 | 605 (45.2%) | 3503 (66.4%) | 106 (47.5%) | 4214 (61.6%) | |
| M1 | 516 (38.6%) | 1631 (30.9%) | 46 (20.6%) | 2193 (32.1%) | |
| Missing | 217 (16.2%) | 142 (2.7%) | 71 (31.8%) | 430 (6.3%) | |
| Histopathology, no (%) | |||||
| Adenocarcinoma | 1006 (75.2%) | 3624 (68.7%) | 145 (65.0%) | 4775 (69.8%) | |
| Squamous cell carcinoma | 332 (24.8%) | 1652 (31.3%) | 78 (35.0%) | 2062 (30.2%) | |
| Year of diagnosis, no (%) | |||||
| 2005–2009 | 715 (53.4%) | 1250 (23.7%) | 184 (82.5%) | 2149 (31.4%) | |
| 2010–2013 | 435 (32.5%) | 1809 (34.3%) | 16 (7.2%) | 2260 (33.1%) | |
| 2014–2018 | 186 (13.9%) | 2202 (41.7%) | 21 (9.4%) | 2409 (35.2%) | |
| Missing | 2 (0.1%) | 15 (0.3%) | 2 (0.9%) | 19 (0.3%) | |
| Marital status, no (%) | |||||
| Non-married | 760 (56.8%) | 3146 (59.6%) | 115 (51.6%) | 4021 (58.8%) | |
| Married | 578 (43.2%) | 2130 (40.4%) | 108 (48.4%) | 2816 (41.2%) | |
| Education level, no (%) | |||||
| Low (<9 years) | 527 (39.4%) | 1964 (37.2%) | 75 (33.6%) | 2566 (37.5%) | |
| Intermediate (10–12 years) | 442 (33.0%) | 2138 (40.5%) | 72 (32.3%) | 2652 (38.8%) | |
| High (>12 years) | 157 (11.7%) | 965 (18.3%) | 25 (11.2%) | 1147 (16.8%) | |
| Missing | 212 (15.8%) | 209 (4.0%) | 51 (22.9%) | 472 (6.9%) | |
| Planned treatment, no (%) | |||||
| Upfront surgery | 171 (12.8%) | 681 (12.9%) | 153 (68.6%) | 1005 (14.7%) | |
| Neoadjuvant therapy + surgery | 36 (2.7%) | 1293 (24.5%) | 3 (1.3%) | 1332 (19.5%) | |
| Definitive chemoradiotherapy | 24 (1.8%) | 490 (9.3%) | 5 (2.2%) | 519 (7.6%) | |
| Palliation | 1107 (82.7%) | 2812 (53.3%) | 62 (27.8%) | 3981 (58.2%) | |
Clinical T-, N- and M-stage calculated according to the 8th edition of the AJCC/UICC TNM classification system